NewcelX is a clinical-stage biotechnology company with a cell therapy platform enabling the production of off-the-shelf cell-based products for unmet medical needs. Its cell therapy product is in clinical development for ALS, with preclinical studies in other neurodegenerative indications.
Status note Preclinical proof-of-concept program. Phase 3 clinical studies still required for any product candidate.
DOXA platform
Stage not disclosed · ActiveModality: small molecule
Status note Development program for small molecules; no candidate details disclosed in excerpts.
Per-asset detail extracted from the 20-F filed 2026-04-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.